Oral Cancer Clinical Trial
Official title:
Workplace Tobacco Cessation And Oral Cancer Screening Study
Tata Memorial Hospital has initiated Workplace Tobacco Cessation and Oral Cancer Screening Programme in Chemical Industry at Khed, Ratnagiri. Appropriate interventions for tobacco cessation will be carried at monthly intervals for twelve months duration. The tobacco cessation rates based on history will be validated with the urinary cotinine levels.
The prevalence of tobacco use in India among men has been reported to be high in most parts
(generally exceeding 50%). It's use is more common in rural areas as compared to urban areas.
Oral cancer, the main cause of which is tobacco, is common in men in developing countries and
the most common cancer among men in India. The five year survival rate for oral and
pharyngeal cancers even in premier institute like the Tata Memorial Hospital ranges from a
poor 8% (hypo pharynx) to 43% (lower lip). Evidence has shown that cessation is the only
intervention with the potential to reduce tobacco related mortality in the short- term and
medium- term. An emphasis on prevention of tobacco consumption will, in the short run, only
have a limited positive effect on tobacco related morbidity and mortality, as prevention
strategies do not affect existing consumers. Workplace tobacco cessation activities in India
are still in rudimentary stage.
In the proposed study of one year duration, professional help in the form focus group
discussion, one to one counseling and pharmacotherapy will be provided to the employees by a
team of doctors and counsellors from Tata Memorial Hospital. Self reporting of tobacco
history will be validated with Biochemical test. This will add objectivity to the programme,
so that, if successful, it can be replicated as a model to promote tobacco control activities
at other workplaces. Naked eye examination of oral cavity of all employees for detection of
oral pre-cancers and cancers will be done by doctors from the Tata Memorial Hospital. The
employees with lesions may be referred for further management, if required. Nursing staff and
Doctors attached to the industry and from the local referral hospital will be invited to
participate as trainees during the active intervention sessions.
The long term objective of this initiative is to establish a model workplace tobacco
cessation and oral cancer screening programme. It will contribute to the human resource and
infrastructure development for tobacco cessation services at the industrial unit and at the
local referral hospital. Proposed tobacco cessation services in the chemical industry would
be of great help for boosting Anti - Tobacco Activities not only in the particular factory
unit but also in the nearby industrial and residential zone.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Completed |
NCT00158678 -
IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
|
Phase 3 | |
Completed |
NCT00933387 -
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT05030597 -
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
|
N/A | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Recruiting |
NCT03684707 -
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
|
Phase 4 | |
Recruiting |
NCT06130332 -
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
|
Phase 2 | |
Recruiting |
NCT04372914 -
Prevention of Oral DNA Damage by Black Raspberries
|
N/A | |
Active, not recruiting |
NCT03529422 -
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
|
Phase 2 | |
Recruiting |
NCT03686020 -
Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)
|
||
Not yet recruiting |
NCT06060288 -
Diagnostic Accuracy of Mobile Phone Imaging Compared to Conventional Clinical Examination for Oral Cancer Screening
|
||
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Completed |
NCT01418118 -
Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
|
Phase 4 | |
Active, not recruiting |
NCT00232960 -
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
|
N/A | |
Recruiting |
NCT05429099 -
Mandibular Reconstruction Preplanning (ViPMR)
|
Phase 2/Phase 3 | |
Completed |
NCT04614896 -
Use of Ultrasound for Measuring Size of Oral Tongue Cancers
|
N/A | |
Recruiting |
NCT03685409 -
Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions
|
Phase 3 | |
Completed |
NCT00402779 -
Erlotinib Prevention of Oral Cancer (EPOC)
|
Phase 3 | |
Recruiting |
NCT05153733 -
Improved Implant for Reconstruction Purposes After Mandibular Resection
|
N/A |